The Motley Fool

Can this FTSE 250 pharma winner crush the AstraZeneca share price in 2019?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Screen of various price trends, possibly in FTSE 100
Image source: Getty Images.

Shareholders have been waiting for boss Pacal Soriot’s turnaround plans at AstraZeneca (LSE: AZN) to return the FTSE 100 pharmaceutical giant to earnings growth. And while it hasn’t actually happened yet, there’s finally an EPS rise forecast for 2019, and the share price has already been rising in anticipation.

AstraZeneca shares have, in fact, put on 90% over the past five years, though with expected earnings growth still not here yet, that’s pushed forecast P/E multiples to over 20. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

And while I think that’s probably a fair valuation based on the company’s long-term potential, I’m seeing BTG (LSE: BTG) as a similarly attractive proposition but at a significantly lower valuation.

Share price spike

BTG shares jumped by more than 6% Thursday morning after the firm upgraded its full-year growth guidance ahead of first-half results due on 13 November. 

The company’s “better than expected performance” has led it to raise its product sales growth expectations for its Oncology and Vascular portfolios to 15-17%. Overall sales for the full year are expected to be pretty much flat at constant exchange rates, and analysts have a modest 1% EPS growth prediction for the year to March 2019.

Part of BTG’s recent success has been down to the acquisition of Novate Medical, with one result being a wider portfolio of treatments, which should help reduce risk.

For the year ending 31 March, we saw net operating cash flow of £120.7m, leaving the company with £210m in cash and equivalents at year end. The company also said it did “not currently require significant levels of debt financing to operate its business,” which suggests there aren’t going to be any liquidity problems.

Bullishness returning

Despite early rises, investors do seem to have lost their appetite for BTG this year, and we’re looking at a 22% share price fall since the start of 2018. But since mid-July, a 21% price recovery suggests confidence has been returning, and we’re now looking at a five-year gain of 55%.

That looks impressive, but it’s been a volatile period, and BTG has yet to reach the stage of paying dividends. That should start this year, though forecast yields for this year and next are very low at 0.1% to 0.2%.

But on P//E ratios of 16.5 to 17, I see the shares as good value for their long-term growth potential, though I could see more volatility before steady earnings growth sets in.

Dividend growth?

Meanwhile, back at AstraZeneca, we’re looking at a company that was once a big attraction to dividend investors. But since the firm’s loss of key patent protections and its focus on building up its development pipeline (which is very much a long-term process when you’re talking about getting drugs developed, tested and approved), those investors have seen their annual payments remaining flat while inflation has been chipping away at their value. And there’s really no change expected this year or next. 

But then, yields of 3.6% aren’t too bad, especially when that really could represent a bottoming out of the yield. EPS is expected to dip by around 20% this year, but the 11% recovery indicated for 2019 really could be the start of a new period of earnings growth. And that should mean a return to progressive dividends.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic…

And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.

Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…

You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.

That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.

Click here to claim your free copy of this special investing report now!

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and BTG. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.